Agile Therapeutics, a pharmaceutical development company specializing in women’s healthcare products, has received three new patents from the US Patent and Trademark Office (USPTO) with claims related to its contraceptive patch technology. The three new patents add to the company’s existing portfolio and extend protection of the company’s proprietary transdermal technology through at least 2028.

Agile has also received a notice of allowance from the USPTO for trademark Twirla, and conditional acceptance from the FDA to use the proprietary name “Twirla” for its AG200-15 contraceptive patch, pending final agency review prior to NDA approval.

“We are thrilled that the USPTO issued these additional patents – it underscores the proprietary nature of our transdermal technology and enhances the value of our intellectual property estate,” said Al Altomari, president and CEO of Agile Therapeutics. “We are continuing to develop our patent portfolio in key markets around the world and the expansion in the US is a great step forward.”

The issued US patents currently held by Agile Therapeutics that are relevant to AG200-15: US Patent 8,246,978 from August 21, 2012 to 2028, 8,221,785 from July 17, 2012 to 2021, 8,221,784 from July 17, 2012  to 2021, 7,384,650 from June 10, 2008 to 2021 and 7,045,145 from May 16, 2006 to 2021.